CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Genomic landscape of ductal carcinoma in situ and association with progression
-
2019
-
-
Source: Breast Cancer Res Treat. 178(2):307-316
[PDF-259.48 KB]
Details:
-
Alternative Title:Breast Cancer Res Treat
-
Personal Author:
-
Description:Purpose:
The detection rate of breast ductal carcinoma in situ (DCIS) has increased significantly, raising the concern that DCIS is over-diagnosed and over-treated. Therefore, there is an unmet clinical need to better predict the risk of progression among DCIS patients. Our hypothesis is that by combining molecular signatures with clinicopathologic features, we can elucidate the biology of breast cancer progression, and risk-stratify patients with DCIS.
Methods:
Targeted exon-sequencing with a custom panel of 223 genes/regions was performed for 125 DCIS cases. Among them, 60 were from cases having concurrent or subsequent invasive breast cancer (IBC) (DCIS+IBC group), and 65 from cases with no IBC development over a median follow-up of 13 years (DCIS-only group). Copy number alterations in chromosome 1q32, 8q24, 11q13 were analyzed using fluorescence in situ hybridization (FISH). Multivariable logistic regression models were fit to the outcome of DCIS progression to IBC as a function of demographic and clinical features.
Results:
We observed recurrent variants of known IBC-related mutations, and the most commonly mutated genes in DCIS were PIK3CA (34.4%) and TP53 (18.4%). There was an inverse association between PIK3CA kinase domain mutations and progression (Odds Ratio [OR]=10.2, p<0.05). Copy number variations in 1q32 and 8q24 were associated with progression (OR=9.3 and 46, respectively; both p<0.05).
Conclusions:
PIK3CA kinase domain mutations and the absence of copy number gains in DCIS are protective against progression to IBC. These results may guide efforts to distinguish low-risk versus high-risk DCIS.
-
Subjects:
-
Source:
-
Pubmed ID:31420779
-
Pubmed Central ID:PMC6800639
-
Document Type:
-
Funding:
-
Volume:178
-
Issue:2
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
